Thyroid eye disease (TED) is a complex autoimmune disease that is often disfiguring and sight threatening. Recent advances have shifted the treatment paradigm from traditional immunosuppressive therapies such as corticosteroids to targeted biologic agents, such as teprotumumab (TMB; anti-IGF-1R) which has been demonstrated to improve proptosis, diplopia, and inflammatory signs in TED patients. In patients with limited response to teprotumumab, developing new drug targets or repositioning already-approved drugs can bring effective, alternative options. To identify new drug targets for TED, we quantified protein expression in living patients using a non-invasive testing method. Tear fluid samples were collected using Schirmer strips from two groups: control patients without ocular surface disease (n = 30) and TED patients before and after treatment with TMB (n = 22). Proteins were extracted from Schirmer strips and underwent proteomic analysis.